Solvonis Therapeutics (LON:SVNS – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported GBX (0.02) EPS for the quarter, Digital Look Earnings reports.
Solvonis Therapeutics Price Performance
Solvonis Therapeutics stock opened at GBX 0.11 on Wednesday. The company’s 50-day moving average is GBX 0.13 and its 200-day moving average is GBX 0.19. The firm has a market capitalization of £8.69 million and a PE ratio of -0.92. Solvonis Therapeutics has a fifty-two week low of GBX 0.10 and a fifty-two week high of GBX 0.40.
About Solvonis Therapeutics
Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company headquartered in the United Kingdom. The company is developing a proprietary synthetic exosome platform designed to enhance the targeted delivery of therapeutic compounds. By engineering nanoscale vesicles that mimic natural exosomes, Solvonis aims to improve tissue selectivity, increase payload stability and enable efficient transport of small molecules, peptides and nucleic acids across biological barriers.
The company’s lead programs focus on oncology and central nervous system disorders, where delivery challenges have historically limited the efficacy of novel therapeutics.
Further Reading
- Five stocks we like better than Solvonis Therapeutics
- Bitcoin Is Bouncing Back—Here are 2 Ways to Play the Rebound
- The Bull Case for Amprius Technologies Just Got Stronger
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
Receive News & Ratings for Solvonis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solvonis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
